Clinical trials: IgAN
Obstructive Sleep Apnea, IgA Nephropathy
The Effect of OSA on Severity and Prognosis of Patients With IgAN
This study aims to investigate the influence of obstructive sleep apnea hypopnea syndrome (OSA) on the severity and prognosis of patients with IgA nephropathy (IgAN), and to evaluate the therapeutic effect of continuous positive…
- Trial name
- NCT06393036
- Testing
- Continuous Positive Airway Pressure
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy, Berger Disease
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- Trial name
- ORIGIN 3 (NCT04716231)
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Vera Therapeutics, Inc.
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and function in adults with biopsy-confirmed IgA nephropathy.
- Trial name
- A-MECH (NCT07820995)
- Testing
- atrasentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Primary IgA Nephropathy
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal…
- Trial name
- Nefigard (NCT03643965)
- Testing
- Nefecon
- Where
- 142 sites in United States, Argentina and 17 more
- Volunteers
- 365 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy, Glomerular Diseases
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with…
- Trial name
- INTEREST (NCT02954419)
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IGA Nephropathy
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
The purpose of this study is to assess whether a tailored diet, eliminating antigens to which IgA nephropathy patients have demonstrated sensitivity, will have an effect on proteinuria, renal function and other immunological…
- Trial name
- DIIGA (NCT01203007)
- Testing
- Tailored diet, Low antigen content diet
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital
Immunoglobulin A (IgA) Nephropathy
PS-002 for the Treatment of IgA Nephropathy in Adults
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy.
- Trial name
- NCT07182227
- Testing
- PS-002
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Purespring Therapeutics Limited
Immunoglobulin A Nephropathy, Healthy Subjects
Development of a Metabolic Assessment Tool for Chronic Kidney Disease
The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN)…
- Trial name
- NCT01838239
- Testing
- Fish Oil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
IgA Patients, Hydroxychloroquine
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB.
- Trial name
- NCT02942381
- Testing
- Hydroxychloroquine Sulfate
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels.
- Trial name
- NCT05562362
- Testing
- RE-021, sparsentan
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy
Serum and Urinary sCD163 in IgA Nephropathy
IgA nephropathy is a common primary glomerular disease with a highly variable clinical course. Soluble CD163 is a marker associated with monocyte and macrophage activation and may reflect inflammatory activity in kidney disease.
- Trial name
- SCD163-IgAN (NCT07754019)
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Healthy Volunteers
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
- Trial name
- NCT07248865
- Testing
- CLYM116
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Climb Bio, Inc.
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary IgA Nephropathy
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with…
- Trial name
- NCT05799287
- Testing
- Telitacicept
- Where
- 101 sites in China
- Volunteers
- 318 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00599963
- Testing
- paricalcitol
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
IgA Nephropathy (IgAN)
The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy
The goal of this clinical trial is to learn if Shenqi Yishen Granules works to treat IgA Nephropathy in adults. It will also learn about the safety of Shenqi Yishen Granules.
- Trial name
- NCT07360002
- Testing
- Shenqi Yishen Granules
- Volunteers
- 102 people
- Sponsor
- Keda Lu
IgA Nephropathy
Study of Telitacicept in Patients With Refractory IgA Nephropathy
The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy.
- Trial name
- NCT05596708
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine